Reminder: Ligand to Host Analyst Day on November 14th in Chicago
SAN DIEGO-- Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) will host an Analyst Day on Thursday, November 14, 2013 from 9:30 a.m. to 11:30 a.m. Central Time (7:30 a.m. to 9:30 a.m. Pacific Time) in Chicago at the Drake Hotel, 140 East Walton Place. The event will include presentations by the Company’s senior management team covering the following topics:
- Ligand’s unique Shots-on-Goal business model
- The transformation of the Company and accelerating value creation
- New information about portfolio assets, partners and milestones
- Highlights of Ligand’s research and technology
- Overview of lead diabetes development program
- 2014 to 2016 financial outlook
The program will also feature a presentation on the medical landscape and patient needs relating to the treatment of menopausal symptoms by Cynthia A. Stuenkel, MD, Clinical Professor of Medicine at the University of California, San Diego School of Medicine.
The presentations will be webcast live and can be accessed at www.ligand.com. A replay of this webcast will be available for 90 days following the event.
About Cynthia A. Stuenkel, MD
Dr. Stuenkel is a Clinical Professor of Medicine at the University of California, San Diego (UCSD) School of Medicine and an attending physician for their Endocrinology and Metabolism Service. At UCSD in 1988 she established one of the first menopause clinics in the US. She lectures nationally and internationally regarding management of postmenopausal women and hormone therapy, cardiovascular disease, osteoporosis, and breast cancer prevention. In 2012, Dr. Stuenkel helped develop and then served as the National Spokesperson for the Endocrine Society's Hormone Health Network Menopause Map. She previously coauthored menopause educational materials as a member of the Hormone Foundation's Women's Health Task Force. A Founding Member and Past President of the North American Menopause Society (NAMS) and two-term member of the NAMS Board of Trustees, Dr. Stuenkel served as the Scientific Chair for the 23rd NAMS Annual Meeting in 2012 and was awarded the Leon Speroff Outstanding Educator Award. She serves on the Editorial Board of Menopause and the Advisory Panels for the NAMS 2007, 2008, 2010, and 2012 Hormone Therapy Position Statements. She was instrumental in the development of the first NAMS/APGO (Association of Professors of Gynecology and Obstetrics) menopause curriculum released in 2012, Contemporary Clinical Management of Menopause. She recently participated in several Medscape productions and as a WebMD Menopause Expert. She was a contributing author of the American College of Obstetricians and Gynecologists 2004 Statement on Hormone Therapy and served on the Editorial Board of their consumer publication, Pause. Dr. Stuenkel served as a clinical investigator in pivotal clinical trials including the Heart and Estrogen/Progestin Replacement Study (HERS), Raloxifene Use for the Heart (RUTH), and Long-Term Interventions on Fractures with Tibolone (LIFT). She has authored or coauthored editorials, reviews, and book chapters and has appeared in local, national, and international media.
About Ligand Pharmaceuticals
Ligand is a biopharmaceutical company focused on assembling a large portfolio of revenue generating assets through licensing and acquisition with the goal to generate sustainable cash-flow and profitability. Ligand has a diverse asset portfolio addressing the unmet medical needs of patients for a broad spectrum of diseases including thrombocytopenia, multiple myeloma, diabetes, hepatitis, muscle wasting, dyslipidemia, anemia and osteoporosis. Ligand’s Captisol platform technology is a patent-protected, chemically modified cyclodextrin with a structure designed to optimize the solubility and stability of drugs. Ligand has established multiple alliances with the world's leading pharmaceutical companies including GlaxoSmithKline, Onyx Pharmaceuticals (a subsidiary of Amgen Inc.), Merck, Pfizer, Baxter International, Bristol-Myers Squibb, Lundbeck Inc., Eli Lilly & Co. and Spectrum Pharmaceuticals. Please visit www.captisol.com for more information on Captisol or www.ligand.com for more information on Ligand.
Follow Ligand on Twitter @Ligand_LGND.
Ligand Pharmaceuticals Incorporated
John Higgins, President and CEO
Don Markley, 310-691-7100
Source: Ligand Pharmaceuticals Incorporated
Released November 7, 2013